tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Geoff Meacham, 138 are a HOLD (31.65%), 269 are a BUY (61.7%), 29 are a SELL (6.65%).
Analyst Geoff Meacham, currently employed at BAML, carries an average stock price target met ratio of 63.28% that have a potential upside of 30.9% achieved within 238 days.
Geoff Meacham’s has documented 860 price targets and ratings displayed on 60 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on KYMR, Kymera Therapeutics at 02-Mar-2026.
Analyst best performing recommendations are on LYEL (LYELL IMMUNOPHARMA).
The best stock recommendation documented was for LYEL (LYELL IMMUNOPHARMA) at 10/30/2024. The price target of $20 was fulfilled within 2 days with a profit of $2.84 (16.55%) receiving and performance score of 82.75.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 05-May-2021
$205
$22.5 (12.33%)
4 years 10 months 3 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold Since 23-Mar-2021
$173
$-9.5 (-5.21%)
$156
4 years 10 months 5 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold Since 14-Dec-2020
$190
4 years 10 months 10 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Buy Since 06-Sep-2019
$175
$-7.5 (-4.11%)
$165
5 years 1 months 4 days ago
(04-Feb-2021)
3/3 (100%)
$19.41 (12.48%)
397
Hold Since 04-Feb-2021
$166
$-16.5 (-9.04%)
$175
5 years 1 months 4 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Which stock is Geoff Meacham is most bullish on?
Which stock is Geoff Meacham is most reserved on?
What Year was the first public recommendation made by Geoff Meacham?
